Oncodesign Precision Med... Stock Quote ALOPM - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

0.358

Bid

0.358

Ask

0.37

Volume

2,209

0.358 Day's Range 0.36

0.33 52 Week Range 1.68

Market Cap

6.512M

Previous Close

0.36

Open

0.358

Last Trade

202

0.358

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

14,028

Shares Outstanding

18,190,878

Dividend Yield

PE Ratio

-0.81

Earnings Per Share (EPS)

-0.44

Revenue

1.08M

Net Profit

-8.09M

Sector

Electromedical Apparatus

Industry

Electromedical Apparatus

Website

www.oncodesign.com

Headquarters

Dijon, Cote-d'or, Fra

Founded

Oncodesign Precision Medicine SA is listed in the Electromedical Apparatus sector of the Euronext with ticker ALOPM. The last closing price for Oncodesign Precision Med... was 0.36 €. Over the last year, Oncodesign Precision Med... shares have traded in a share price range of 0.33 € to 1.68 €.

Oncodesign Precision Med... currently has 18,190,878 shares outstanding. The market capitalization of Oncodesign Precision Med... is 6.55 € million. Oncodesign Precision Med... has a price to earnings ratio (PE ratio) of -0.81.

Oncodesign Precision Medicine : Bilan semestriel du contrat de liquidité confié à la société TP ICAP (Europe)

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ; Mnémonique : ALOPM), entreprise biopharmaceutique spécialisée en...

Oncodesign Precision Medicine reprend les droits sur son programme OPM-201 auprès de Servier après une phase I volontaires sains positive

Reprise par OPM de l’intégralité des droits du programme OPM-201 et du portefeuille de brevets associé Confirmation de l’innocuité de la...

OPM détaille les résultats finaux de son étude de phase 1 avec OPM-101, inhibiteur de la cible RIPK2, avec des données de sécurité solides sans toxicité cardiaque, ouvrant la voie au lancement de la phase 1b/2a

Finalisation du rapport d’étude de l’essai de phase 1 de l’OPM-101 contrôlé par placebo en double aveugle chez 104 volontaires sains (VS) ayant...

OPM Announces Poster Presentation on OPM-101, a RIPK2 Kinase Inhibitor, in Healthy Volunteers at UEG Week 2024 Conference

Presentation by Professor Laurent Peyrin-Biroulet (M.D., PhD Professor of Gastroenterology at CHRU of Nancy) and Bruno Robin (PharmD, Head of OPM...

OPM annonce ses résultats du premier semestre 2024 et fait le point sur ses développements cliniques, et sa situation financière

OPM-101 conclut positivement sa Phase 1 volontaires sains permettant de prévoir le démarrage d'un essai clinique de Phase 1b/2a, fin 2024 début...

OPM annonce les résultats positifs de la phase 1 volontaires sains d’OPM-101 : engagement significatif de la cible avec un excellent profil de sécurité

Fin de l’essai de phase 1 avec OPM-101 contrôlé par placebo et en double aveugle : 104 volontaires sains (VS) ont participé à cet essai visant à...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.007	1.9943019943	0.351	0.365	0.34	5635	0.3468949	DE
4	-0.102	-22.1739130435	0.46	0.46	0.33	12547	0.38192995	DE
12	-0.462	-56.3414634146	0.82	0.82	0.33	14028	0.50641868	DE
26	-0.622	-63.4693877551	0.98	1.38	0.33	11762	0.77440346	DE
52	-1.052	-74.609929078	1.41	1.68	0.33	11308	0.98986806	DE
156	-0.632	-63.8383838384	0.99	2.39	0.33	10966	1.33511753	DE
260	-0.632	-63.8383838384	0.99	2.39	0.33	10966	1.33511753	DE

ALOPM - Frequently Asked Questions (FAQ)

What is the current Oncodesign Precision Med... share price?

The current share price of Oncodesign Precision Med... is 0.358 €

How many Oncodesign Precision Med... shares are in issue?

Oncodesign Precision Med... has 18,190,878 shares in issue

What is the market cap of Oncodesign Precision Med...?

The market capitalisation of Oncodesign Precision Med... is EUR 6.55M

What is the 1 year trading range for Oncodesign Precision Med... share price?

Oncodesign Precision Med... has traded in the range of 0.33 € to 1.68 € during the past year

What is the PE ratio of Oncodesign Precision Med...?

The price to earnings ratio of Oncodesign Precision Med... is -0.81

What is the cash to sales ratio of Oncodesign Precision Med...?

The cash to sales ratio of Oncodesign Precision Med... is 6.07

What is the reporting currency for Oncodesign Precision Med...?

Oncodesign Precision Med... reports financial results in EUR

What is the latest annual turnover for Oncodesign Precision Med...?

The latest annual turnover of Oncodesign Precision Med... is EUR 1.08M

What is the latest annual profit for Oncodesign Precision Med...?

The latest annual profit of Oncodesign Precision Med... is EUR -8.09M

What is the registered address of Oncodesign Precision Med...?

The registered address for Oncodesign Precision Med... is 18 RUE JEAN MAZEN, DIJON, COTE-D'OR, 21000

What is the Oncodesign Precision Med... website address?

The website address for Oncodesign Precision Med... is www.oncodesign.com

Which industry sector does Oncodesign Precision Med... operate in?

Oncodesign Precision Med... operates in the ELECTROMEDICAL APPARATUS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CLEXCumulex NV	0.88 € (43.09%)	100
MLOCTOctopus Biosafety	0.134 € (34.00%)	101
MLWEYWeya	0.019 € (26.67%)	3.25k
ALEUPEuroplasma	0.0138 € (24.32%)	97.44M
POXELPoxel	0.22 € (24.29%)	5.01M
ALKLAKlarsen	0.761 € (-50.90%)	493.15k
ALCYBCybergun	0.0001 € (-50.00%)	68.51M
SGDDSSpineguard DS	0.0001 € (-50.00%)	778.85k
DMSBSDiagnostic Medical Systems	0.005 € (-50.00%)	3k
HAFDSHaffner Energy DS	0.013 € (-39.53%)	278.57k
ATOAtos SE	0.004 € (8.11%)	1.16B
BCPBanco Comercial Portugues SA	0.5448 € (-0.91%)	152.4M
ALALOAcheterLouerFR	0.0022 € (4.76%)	99.26M
ALEUPEuroplasma	0.0138 € (24.32%)	97.44M
ALCYBCybergun	0.0001 € (-50.00%)	68.51M

1jas 3 minutes ago

Late filings just like so many OTC and Nasdaq companies.

AFFU

BullNBear52 3 minutes ago

What they are doing today is not journalism as I explained what the lede is. It now takes several paragraphs to explain the headline. Perhaps Hester should write her own articles.

ddls 6 minutes ago

Sales-Track showing steep sales-declines at (BIEL) BioElectronics....😭

Go BIEL!!!

BIEL

danieldeubank 6 minutes ago

The Executive Order titled "Immediate Measures to Increase American Mineral Production," issued on March 20, 2025, aims to bolster domestic mineral production by streamlining permitting, prioritizing critical projects, and reducing reliance on foreign mineral supplies. Below is an analysis of how it

downdraft 7 minutes ago

TPTW - Ultimate Sleeper? Super App in development for 7 years, now in Beta, with numerous press releases this month!

What's a Super App? Think WeChat, in Asia. All-in-one social media, shopping entertainment, etc. How big is WeChat? Somewhere around $20 billion of annual revenue!

TPTW

lettruthringout 7 minutes ago

So, yesterday was triple witching day

That is partial explanation for high volume at end of day. However, as noted earlier - there were 15 million shares traded. The highest number before that was 9.8 million on March 15 2024 (also triple-witching); next highest was 5.5 million one d

WTTR

TheFollower 8 minutes ago

I don't believe you understood the original question. or didn't read it.

NWBO

firehorse 8 minutes ago

Do they have a transfer agent? I was told no transfer agent is the reason shares were removed and they would be reinstated if the stock reinstated a transfer agent

IPLY

PEACHMAN 8 minutes ago

Holding IFUS share from .004 is not a temporary pump.

The truth is IFUS management is building the company the right way locally,nationally,and internationally.

A few minutes of reading the news from IFUS will tell everyone that paid bashers are Lying

ht

IFUS

europa7 8 minutes ago

How Is Tokenization Changing The Way We Invest?
Mar 06, 2025
https://hedera.com/blog/how-is-tokenization-changing-the-way-we-invest
***
***
NOTE: an interesting example below of the potential variety and volume of real world assets (RWA) that might be tokenized in

HBARUSD

rooster 11 minutes ago

Yep… https://x.com/gunthereagleman/status/1903446171667833207?s=46&t=qLQnO1TjeygtFbhEqQdlmg

Major Profits 12 minutes ago

"You haven't a clue what the new tier entails and neither do I,"
I dunno about that as I would think that those who read this might have some kind of clue. Why else publish it?

https://blog.otcmarkets.com/2024/10/14/the-evolution-of-the-otc-market-introducing-otcid/
Ef

GVSI

Nerd Beautiful 12 minutes ago

Liquidmetal hinges solve the crease problem because they’re more than a hinge. Micro gears raise and lower a central spine while the outer edges open and close. When closed the spine drops to allow a teardrop shape in the screen. When open the spine rises to support the central part of the screen th

LQMT

Krungster10 13 minutes ago

Sounds like you have some type of hero complex to think you are out here saving grown folks that are making their own financial decisions. Who are you to tell anyone what not to buy with their own money?

ASII

Truthsocial 13 minutes ago

Exactly absolutely

RDGL

Bigfootbud 15 minutes ago

Ok, cool! Looks like trumpcancer.com has been registered since 7/25/2005!! Long time!
and... trumpcancer.org registered fairly recently...

WHOIS search results
Domain Information
Name TRUMPCANCER.COM
Registry Domain ID 189029673_DOMAIN_COM-VRSN
Re

VRSN

fung_derf 15 minutes ago

Keep howling at the moon Fung. Nobody is selling $DBMM.

Or buying it seems.
Therefore, no one need post here and yet here you are!

DBMM

Ayock 15 minutes ago

Your cult doesn't seem to care...

https://scontent-lax3-1.xx.fbcdn.net/v/t39.30808-6/485739739_1125751009656472_2638257754763246620_n.jpg?_nc_cat=110&ccb=1-7&_nc_sid=833d8c&_nc_ohc=HIFOXUeljRQQ7kNvgGrTA7E&_nc_oc=Adn0mhz5WMG-x509_zDcd6MVHfJ6fcxqBTy9s64GUlNo8agAot8eeruhg_067v4UsOBzoWnSo

Steady_T 16 minutes ago

Once approval comes, your threatened lawsuit will be years before it could possibly have results, assuming it is not dismissed early on.

Not something I'm worried about at the present time.

NWBO

Bubae 17 minutes ago

Do your really think anyone is buying that line. You will need to do better to flip your position. $11 a shares. Meanwhile the weekly conversions continue next week with a basis price of $0.0003. You think maybe they should be holding for $11.00. The price of ECVO at $11.00 is a very thinly and very

ASII

ddls 17 minutes ago

Yes, thanks for all the BIEL-bullshit throughout the-years. 🤠

One more week and my March share volume comes out.

I can tell you as of current numbers they're not looking too good.

The pumpaholoic's better come up with something good this week or M

BIEL

WALLnut 17 minutes ago

You wouldn’t know “keeping it real” if it smacked you in the face. Your entire argument is built on a deliberate misrepresentation of what makes a medical technology valuable.

Yes, RadioGel’s original patents are old—but you conveniently ignore the fact that Vivos has developed and se

RDGL

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Oncodesign Precision Medicine SA (ALOPM)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

About Oncodesign Precision Medicine SA

Ask ADVFN Intelligence (AI)

ALOPM Latest News

Oncodesign Precision Medicine : Bilan semestriel du contrat de liquidité confié à la société TP ICAP (Europe)

Oncodesign Precision Medicine reprend les droits sur son programme OPM-201 auprès de Servier après une phase I volontaires sains positive

OPM détaille les résultats finaux de son étude de phase 1 avec OPM-101, inhibiteur de la cible RIPK2, avec des données de sécurité solides sans toxicité cardiaque, ouvrant la voie au lancement de la phase 1b/2a

OPM Announces Poster Presentation on OPM-101, a RIPK2 Kinase Inhibitor, in Healthy Volunteers at UEG Week 2024 Conference

OPM annonce ses résultats du premier semestre 2024 et fait le point sur ses développements cliniques, et sa situation financière

OPM annonce les résultats positifs de la phase 1 volontaires sains d’OPM-101 : engagement significatif de la cible avec un excellent profil de sécurité

Oncodesign Precision Medicine : Bilan semestriel du contrat de liquidité confié à la société TP ICAP (Europe)

Oncodesign Precision Medicine reprend les droits sur son programme OPM-201 auprès de Servier après une phase I volontaires sains positive

OPM détaille les résultats finaux de son étude de phase 1 avec OPM-101, inhibiteur de la cible RIPK2, avec des données de sécurité solides sans toxicité cardiaque, ouvrant la voie au lancement de la phase 1b/2a

OPM annonce la présentation d’un poster sur OPM-101, inhibiteur de la kinase RIPK2, chez les volontaires sains lors du congrès de l’UEG Week 2024

OPM Announces Its First-half 2024 Results and Provides an Update on Its Clinical Developments, and Its Financial Situation

OPM annonce les résultats positifs de la phase 1 volontaires sains d’OPM-101 : engagement significatif de la cible avec un excellent profil de sécurité

Oncodesign Precision Medicine : Bilan semestriel du contrat de liquidité confié à la société TP ICAP (Europe)

Oncodesign Precision Medicine : Apport complémentaire au contrat de liquidité

ALOPM - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Oncodesign Precision Medicine SA (ALOPM) Quote

Oncodesign Precision Medicine SA (ALOPM)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

About Oncodesign Precision Medicine SA

Ask ADVFN Intelligence (AI)

ALOPM Latest News

Oncodesign Precision Medicine : Bilan semestriel du contrat de liquidité confié à la société TP ICAP (Europe)

Oncodesign Precision Medicine reprend les droits sur son programme OPM-201 auprès de Servier après une phase I volontaires sains positive

OPM détaille les résultats finaux de son étude de phase 1 avec OPM-101, inhibiteur de la cible RIPK2, avec des données de sécurité solides sans toxicité cardiaque, ouvrant la voie au lancement de la phase 1b/2a

OPM Announces Poster Presentation on OPM-101, a RIPK2 Kinase Inhibitor, in Healthy Volunteers at UEG Week 2024 Conference

OPM annonce ses résultats du premier semestre 2024 et fait le point sur ses développements cliniques, et sa situation financière

OPM annonce les résultats positifs de la phase 1 volontaires sains d’OPM-101 : engagement significatif de la cible avec un excellent profil de sécurité

Oncodesign Precision Medicine : Bilan semestriel du contrat de liquidité confié à la société TP ICAP (Europe)

Oncodesign Precision Medicine reprend les droits sur son programme OPM-201 auprès de Servier après une phase I volontaires sains positive

OPM détaille les résultats finaux de son étude de phase 1 avec OPM-101, inhibiteur de la cible RIPK2, avec des données de sécurité solides sans toxicité cardiaque, ouvrant la voie au lancement de la phase 1b/2a

OPM annonce la présentation d’un poster sur OPM-101, inhibiteur de la kinase RIPK2, chez les volontaires sains lors du congrès de l’UEG Week 2024

OPM Announces Its First-half 2024 Results and Provides an Update on Its Clinical Developments, and Its Financial Situation

OPM annonce les résultats positifs de la phase 1 volontaires sains d’OPM-101 : engagement significatif de la cible avec un excellent profil de sécurité

Oncodesign Precision Medicine : Bilan semestriel du contrat de liquidité confié à la société TP ICAP (Europe)

Oncodesign Precision Medicine : Apport complémentaire au contrat de liquidité

ALOPM - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free